Therapeutic Exploratory (Phase II)

3,454 trials 1,368 recruiting

Filter these 3,454 trials by condition, country, sponsor and more.

Open in Search →

Safety, tolerability, and efficacy of ACOU085 for prevention of hearing loss in testicular cancer patients receiving cisplatin Ended

2023-503696-15-00 sensorineural hearing loss (SNHL) 2023-11-10
An Open-Label, Phase 2, Safety, and Efficacy Study of Ruxolitinib Cream in Participants With Genital Vitiligo Ended

2023-503737-22-00 Nonsegmental vitiligo with genital involvement 2023-11-08
Improvement of Quality of Life by Cannabinoids in Oncologic Patients (BELCANTO) Ended

2024-518917-24-00 oncology, palliative care, quality of life 2023-11-08
A study on the immune response and safety of an RSV vaccine when given to adults 18 years of age and above who received lung or kidney trans… Ended

2023-503951-81-00 Respiratory Syncytial Virus Infections 2023-11-07
A trial to evaluate the efficacy and safety of different doses of LEO 138559 in adults with moderate-to-severe atopic dermatitis. Ended

2022-500777-14-00 Atopic Dermatitis 2023-11-06
A Phase 2 Safety and Immunogenicity Study of a Monovalent Pneumococcal Conjugate Candidate in Healthy Toddlers Ended

2023-505154-18-00 Pneumococcal Infections 2023-11-02
A Study to Evaluate Linsitinib in Subjects with Active, Moderate to Severe Thyroid Eye Disease (TED) Ended

2022-502812-35-00 Thyroid Eye Disease 2023-10-26
A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis (PALIZADE) Ended

2022-502227-22-00 Autoimmune disease 2023-10-25
A Phase 2 Study Evaluating INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma Ended

2022-502476-23-00 Treatment of immunotherapy-naive patients with previous 2023-10-25
A Study to Investigate MBS2320 Patients with IPF Ended

2023-504418-30-00 Idiopathic Pulmonary Fibrosis 2023-10-24
Safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SAR442501 in pediatric participants with Achondroplasia Ended

2023-503677-37-00 Osteochondrodysplasia 2023-10-24
Detection of tumor DNA in the blood of patients receiving standard therapy for hormone receptorpositive (HR+) non-HER2 expressing (HER2-) me… Ended

2022-502372-22-01 Metastatic Breast Cancer HR+, HER2- 2023-10-19
A study to investigate the safety, tolerability and preliminary efficacy of NGI226 microparticles in patients with Achilles tendinopathy Ended

2022-500863-10-00 Achilles Tendinopathy 2023-10-18
A clinical trial to investigate efficacy and safety of NT 201 injections compared with placebo injections in participants aged 18 years and … Ended

2022-501461-52-00 Moderate to severe chronic peripheral neuropathic pain 2023-10-17
Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy (EXPA… Ended

2023-503830-27-00 Large B-Cell Lymphoma (LBCL) 2023-10-17
A Phase 2, Multicenter, Open-Label Study of DKN-01 in Combination with Tislelizumab ± Chemotherapy as First Line or Second-Line Therapy in A… Ended

2023-504940-32-00 Gastric cancer 2023-10-13
Study of GS-5718 in Participants With Cutaneous Lupus Erythematosus (CLE) Ended

2022-501523-24-00 Cutaneous Lupus Erythematosus (CLE) 2023-10-12
Milademetan and fulvestrant in GATA3-mutant, ER-positive, HER2-negative advanced or metastatic breast cancer patients (DEMETER) Ended

2022-502360-21-00 GATA3-mutant, ER-positive, HER2-negative advanced or me 2023-10-12
A Phase 2, Double-Blind, Randomized, 16-Week, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Open-Label E… Ended

2022-502827-23-00 Chronic Hand Eczema 2023-10-12
Orchid 1 Ended

2023-503516-32-00 Vulvar lichen sclerosus (VLS) 2023-10-12
A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced HR Positive and HER2-Negative BC Ended

2023-503903-27-00 metastatic or locally advanced Hormone Receptor positiv 2023-10-11
Effects of empagliflozin on plasma glucose in patients with HNF1A-MODY: a randomized, double-blind, crossover trial Ended

2023-503760-17-00 Maturity-onset diabetes of the young type 3 (HNF1A-MODY 2023-10-11
A MULTICENTER, SINGLE-ARM, THREE COHORT, PHASE II TRIAL OF PATRITUMAB DERUXTECAN (HER3-DXD) IN PATIENTS WITH ACTIVE BRAIN METASTASES FROM HE… Ended

2023-503251-10-00 Metastatic Breast Cancer or Advanced Non-Small Cell Lun 2023-10-10
An Exploratory, Multicenter, Randomized, double-blind, placebo-controlled study evaluating the effect and safety of pitolisant in children a… Ended

2023-503678-18-00 Autism spectrum disorders 2023-10-10